Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CDA | P32320 | 1/20 | 0.35 |
| ▸ | ADK | P55263 | 1/20 | 0.34 |
| ▸ | PYGM | P11217 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 8/20 | 0.32 |
| ▸ | CA2 | P00918 | 8/20 | 0.32 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | PNP | P00491 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5134126 | 1.00 | GSK3B (0.38) | GSK3BCDAADKPYGMOGA | |
| SCHEMBL8810431 | 1.00 | GSK3B (0.38) | GSK3BCDAADKPYGMOGA | |
| SCHEMBL6887314 | 0.89 | GSK3B (0.47) | GSK3BADKPYGMTSHRCA1 | |
| SCHEMBL6888278 | 0.84 | GSK3B (0.38) | GSK3BADKPYGMTSHRCA1 | |
| SCHEMBL4286250 | 0.78 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL3363495 | 0.78 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL5697577 | 0.78 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL11198199 | 0.78 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL6889028 | 0.78 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 | |
| SCHEMBL3718127 | 0.78 | GSK3B (0.47) | GSK3BADKTSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| EP-2968228-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | Quadex Pharmaceuticals, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160369-A1 | COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES | QUADEX PHARMACEUTICALS, LLC (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2601289-A2 | REPROGRAMMING IMMORTALIZED B CELLS | Cellular Dynamics International, Inc. (US) | 2013-06-12 | — | — | EP | disclosed |
| EP-2558478-A1 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE | Somalogic, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2012018933-A2 | REPROGRAMMING IMMORTALIZED B CELLS | CELLULAR DYNAMICS INTERNATIONAL, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2011130289-A1 | 5-POSITION MODIFIED PYRIMIDINES AND THEIR USE | SOMALOGIC, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2006023774-A2 | PLASMA OR SERUM FRACTION FOR TREATMENT AND PREVENTION OF VIRAL INFECTIONS AND RELATED CONDITIONS | IMQUEST BIOSCIENCES, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-1585527-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004064846-A1 | COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY | GILEAD SCIENCES, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2003091264-A2 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003000200-A2 | β-2'-OR 3'-HALONUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1165570-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-1997035868-A9 | UREA NUCLEOSIDES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | — | 1997-12-24 | — | — | WO | disclosed |
| WO-1997035868-A1 | UREA NUCLEOSIDES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-10-02 | — | — | WO | disclosed |
| WO-1997007829-A1 | NOVEL IMAGING AGENTS AND METHODS FOR THE PREPARATION AND USE THEREOF | UNIVERSITY ADVANCED BIO-IMAGING ASSOCIATES (US) | 1997-03-06 | — | — | WO | disclosed |